March 12, 2020
Evonik declares force majeure for ThreAMINO® supply due to COVID-19 outbreak
Due to the COVID-19 outbreak, Evonik's contract manufacturer had to shut-down its production facilities, Evonik reported March 11. Both production and shipping of the amino acid ThreAMINO® are affected.
Dr. Emmanuel Auer, head of Animal Nutrition Business Line at Evonik, explained: "Regrettably, we are facing a supply shortage for ThreAMINO. We have therefore decided to send a Force Majeure notification to our customers with immediate effect, in accordance with our contracts. Meanwhile, we try the utmost to mitigate this situation and re-establish supply to our customers as fast as possible."
Evonik is keeping its customers regularly informed as the situation develops.